Amanda Nickles-Fader, MD
Gynecologic Oncology · Baltimore, MDNPI 1770750598
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,175 of the $21,271 with a category attached, or 71.3%. 7 manufacturers reported payments, led by Eisai Inc. at 54.4% of the total. Reporting peaked in 2021 at $11,563 and has fallen 58.9% since, to $4,750 in 2025. Among gynecologic oncology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $1636.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$12K
- GSK$7K
- Merck$2K
- AstraZeneca$900
- Boston Scientific$131
- Genmab U.S., Inc.$40
- plus $18 from 1 others
Across 2 payments — averaging $8692.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$17K
What the payments were for
- Consulting fees$15,17571%
- Speaking & faculty fees$4,75022%
- Grants$9004%
- Travel & lodging$1501%
- Food & beverage$2961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $11,563 |
| GSK | 3 | $6,969 |
| Merck | 3 | $1,650 |
| AstraZeneca | 1 | $900 |
| Boston Scientific | 1 | $131 |
| Genmab U.S., Inc. | 1 | $40 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$11,563
- Solyx SIS System$131
How this compares
$21,271 in reported general payments places this provider in the 90th percentile of 35 gynecologic oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 24 | $427 |
| Prochlorperazine Maleate | 11 | $321 |
| Dexamethasone | 13 | $287 |
| Ondansetron Hcl | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Baltimore
- Dwight ImBaltimore$93K
- Kara Long RocheBaltimore$5K
- Neil RosensheinBaltimore$5K
- Sarah LynamBaltimore$3K
- Amanda RamosBaltimore$3K
- Beman KhulpateeaBaltimore$2K
- Dana RoqueBaltimore$2K
- Christine O ConnorBaltimore$1K
- Hyung RyuBaltimore$973
- Teresa Diaz-MontesBaltimore$887
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.